Vanguard Fiduciary Trust
QNCX icon

Vanguard Fiduciary Trust’s Quince Therapeutics QNCX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.7K Buy
3,614
+2,452
+211% +$56.4K ﹤0.01% 3812
2026
Q1 		$23.5K Buy
+1,162
New +$233K ﹤0.01% 3930

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust's QNCX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Quince Therapeutics (QNCX) stake by 211% in Q2 2026, buying an estimated $56.4K and bringing the position to 3,614 shares worth $65.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3812.

Vanguard Fiduciary Trust first reported a position in QNCX in Q1 2026 and has held it in 2 quarters since. 25 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Vanguard Fiduciary Trust held 3,614 shares of Quince Therapeutics worth $65.7K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 2,452 Quince Therapeutics shares in Q2 2026, an estimated $56.4K.
  • Quince Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3812 holding.
  • Vanguard Fiduciary Trust first reported a position in Quince Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 25 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.